SCHEMBL769912

SCHEMBL769912

O=C(O)c1ccccc1NC1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.48
DNPH1 O43598 7/20 0.44
P2RY12 Q9H244 1/20 0.44
P2RY2 P41231 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
AMDHD2 Q9Y303 1/20 0.40
P2RY4 P51582 1/20 0.40
ATIC P31939 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
IMPDH2 P12268 1/20 0.39
LDHA P00338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29508765 1.00 FBP1 (0.48) FBP1DNPH1P2RY12P2RY2SIRT2
SCHEMBL14742691 1.00 FBP1 (0.48) FBP1DNPH1P2RY12P2RY2SIRT2
Pyrophosphoric Acid SCHEMBL14742591 0.97 FBP1 (0.45) FBP1DNPH1P2RY12P2RY2SIRT2
SCHEMBL2818963 0.83 FBP1 (0.55) FBP1DNPH1P2RY12P2RY2AMDHD2
SCHEMBL1513025 0.83 FBP1 (0.55) FBP1DNPH1P2RY12P2RY2AMDHD2
SCHEMBL3290451 0.81 SLC5A2 (0.53)
SCHEMBL379657 0.78 ADORA1 (0.41)
SCHEMBL5922579 0.78 FBP1 (0.49) FBP1DNPH1P2RY12P2RY2ATIC
SCHEMBL851261 0.74 DHODH (0.37)
SCHEMBL30853963 0.72 FBP1 (0.48) FBP1DNPH1P2RY2SIRT2SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092179-A1 GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF OCTARINE BIO APS (DK) 2026-04-02 US claimed
US-20240254533-A1 METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES OCTARINE BIO APS (DK) 2024-08-01 US claimed
EP-4347856-A2 METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES Octarine Bio ApS (DK) 2024-04-10 EP claimed
WO-2024068434-A2 GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF OCTARINE BIO APS (DK) 2024-04-04 WO claimed
WO-2022248635-A2 METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES. OCTARINE BIO APS (DK) 2022-12-01 WO claimed
US-20190032014-A1 USING MICROBIOTA METABOLITES TO DIFFERENTIATE NAÏVE T-CELLS AND RELATED METHODS TO INDUCE OR PREVENT INFLAMMATORY CONDITIONS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2019-01-31 US claimed
EP-3430128-A1 USING MICROBIOTA METABOLITES OT DIFFERENTIATE NAIVE T-CELLS AND RELATED METHODS TO INDUCE OR PREVENT INFLAMMATORY CONDITIONS The Texas A&M University System (US) 2019-01-23 EP claimed
WO-2017161268-A1 USING MICROBIOTA METABOLITES OT DIFFERENTIATE NAIVE T-CELLS AND RELATED METHODS TO INDUCE OR PREVENT INFLAMMATORY CONDITIONS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2017-09-21 WO claimed
US-20150299742-A1 COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2015-10-22 US claimed
US-20100210017-A1 COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE 2010-08-19 US claimed
EP-2126042-A2 COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS The Regents of the University of Colorado (US) 2009-12-02 EP claimed
WO-2008089102-A2 COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS REGENTS OF THE UNIVERSITY OF COLORADO (US) 2008-07-24 WO claimed
EP-4739326-A2 PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA SNIPR Biome ApS (DK) 2026-05-13 EP disclosed
EP-4739777-A1 TRANSMISSIBLE ELEMENTS COMPRISING PATHWAY MODIFICATION SYSTEMS AND EXOGENOUS NUCLEIC ACIDS FOR THE PRODUCTION OF MOLECULES OF INTEREST SNIPR Biome ApS (DK) 2026-05-13 EP disclosed
US-20260125432-A1 MALTOSE DEPENDENT DEGRONS, MALTOSE-RESPONSIVE PROMOTERS, STABILIZATION CONSTRUCTS, AND THEIR USE IN PRODUCTION OF NON-CATABOLIC COMPOUNDS AMYRIS INC (US) 2026-05-07 US disclosed
US-20260115234-A1 PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA SNIPR BIOME APS (DK) 2026-04-30 US disclosed
EP-0698218-A1 LABELLED CARBOHYDRATES AND THEIR USE IN ASSAYS Oxford GlycoSciences (UK) Limited (GB) 1996-02-28 EP disclosed
WO-1994028423-A1 LABELLED CARBOHYDRATES AND THEIR USE IN ASSAYS OXFORD GLYCOSYSTEMS LTD. (GB) 1994-12-08 WO disclosed
EP-0608722-A1 Biological screens for detection of herbicides AMERICAN CYANAMID COMPANY (US) 1994-08-03 EP disclosed
US-5034318-A Culturing Coryneform glutamic acid producing bacteria with plasmids AJINOMOTO CO., INC. (JP) 1991-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125432-A1 MALTOSE DEPENDENT DEGRONS, MALTOSE-RESPONSIVE PROMOTERS, STABILIZATION CONSTRUCTS, AND THEIR USE IN PRODUCTION OF NON-CATABOLIC COMPOUNDS MAX, JUND, MYCBP FBP1 38/4885DNPH1 2236/4885P2RY12 4753/4885
US-20260115234-A1 PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA AADAT, NAT1, IDO1 FBP1 66/4885DNPH1 2901/4885P2RY12 3065/4885
US-20260092179-A1 GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF TDO2, BLVRB, INMT FBP1 1134/4885DNPH1 2663/4885P2RY12 4376/4885
US-20190032014-A1 USING MICROBIOTA METABOLITES TO DIFFERENTIATE NAÏVE T-CELLS AND RELATED METHODS TO INDUCE OR PREVENT INFLAMMATORY CONDITIONS CD69, CD14, IL17A FBP1 2571/4885DNPH1 1379/4885P2RY12 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.